


BEITRÄGE DEUTSCHER STUDIENGRUPPEN ZUM MAMMAKARZINOM: ASCO 29.5.-2.6.2015, CHICAGO

Das Jahrestreffen der American Society of Clinical Oncology (ASCO) gilt als der weltweit wichtigste jährliche Krebskongress. Wer seine Forschungsergebnisse hier präsentieren darf, gilt als geadelt in der Welt der Onkologie. Die deutschen Mammakarzinom-Studiengruppen werden jedes Jahr aufs Neue eingeladen, ihre Studienergebnisse vorzustellen. Im Folgenden finden Sie einen kurzen Überblick über die wichtigsten Beiträge. Das Programm finden Sie unter <http://am.asco.org/program>.



ORAL PRESENTATIONS

Date: Sunday, May 31 | 11:30 AM - 1:00 PM

Session Type: Clinical Science Symposium

Session Title: Predicting Response in Triple-Negative and HER2-Positive Breast Cancer: Unlocking Pieces to Solve the Puzzles

Room: E Hall D2, Time: 12:06 PM - 12:18 PM

Presenter: Sibylle Loibl, German Breast Group

Presentation: Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials. Abstract #511

Date: Monday, Jun 1 | 3:00 PM - 6:00 PM

Session Type: Oral Abstract Session

Session Title: Tumor Biology

Room: E450, Time: 4:00 PM - 4:12 PM

Presenter: Amelie Schramm, MD, Universitätsfrauenklinik Ulm

Presentation: Discordance between HER2-phenotype on circulating tumor cells and primary tumor in women with advanced breast cancer.

Abstract #11003

Date: Monday, Jun 1 | 3:00 PM - 6:00 PM

Session Type: Oral Abstract Session

Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Room: N Hall B1, Time: 4:12 PM - 4:24 PM

Presenter: Gunter Von Minckwitz, MD, German Breast Group

Presentation: Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.

Abstract #1004

Date: Monday, Jun 1 | 3:00 PM - 6:00 PM

Session Type: Oral Abstract Session

Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Room: N Hall B1, Time: 5:24 PM - 5:36 PM

Presenter: David Krug, MD, University Hospital Heidelberg

Presentation: Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pCR after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials.

Abstract #1008

POSTER

Date: Saturday, May 30 | 8:00 AM - 11:30 AM

Session Type: Poster Session

Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Room: S Hall A

Presenter: Jenny Furlanetto, German Breast Group

Poster: Death during study treatment: An evaluation of events in 31 German clinical trials.

Abstract #1036

Date: Saturday, May 30 | 8:00 AM - 11:30 AM

Session Type: Poster Session

Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Room: S Hall A

Presenter: Andreas Schneeweiss, MD, Heidelberg University

Poster: A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).

Abstract #TPS1101

Date: Saturday, May 30 | 8:00 AM - 11:30 AM

Session Type: Poster Session

Session Title: Breast Cancer – Triple-Negative/Cytotoxics/Local Therapy

Room: S Hall A

Presenter: Oleg Gluz, MD, West German Study Group

Poster: Efficacy of 12 weeks neoadjuvant nab-paclitaxel combined with carboplatinum vs. gemcitabine in triple-negative breast cancer: WSG-ADAPT TN randomized phase II trial.

Abstract #1032

Date: Saturday, May 30 | 8:00 AM - 11:30 AM

Session Type: Poster Session

Session Title: Breast Cancer – HER2/ER

Room: S Hall A

Presenter: Rachel Wuerstlein, MD, University of Munich

Poster: Significance of prospective multicenter decision impact WSG-BCIST Study in postmenopausal ER+ HER2- N0 early breast cancer (EBC) for molecular testing for intrinsic subtype definition.

Abstract #535

Date: Monday, Jun 1 | 8:00 AM - 11:00 AM

Session Type: Poster Session

Session Title: Breast Cancer – HER2/ER

Room: N Hall B1

Presenter: Nadia Harbeck, MD, PhD, University of Munich

Poster: Efficacy of 12-weeks of neoadjuvant TDMI with or without endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer: WSG-ADAPT HER2+/HR+ phase II trial.

Abstract #506